L'intérêt à découvert pour Branchout Food donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Branchout Food. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Branchout Food (NASDAQ:BOF) Stock, Rapport sur les intérêts à découvert

Branchout Food

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are primarily located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.

Branchout Food inc

Kyoto Financial Group Inc

News

Paramount Says It Secured Approval From Oregon State Agencies For Proposed Technologies And Processes At Its Wholly Owned Grassy Mountain Gold Project

The award followed an open tender and will leverage Baker Hughes' completions technology portfolio and extensive experience in Brazil to optimize production across multiple deepwater fields.

Contracts

Baker Hughes Enters Multi-year Fully Integrated Completions Systems Contract With Petrobras

Financing

EQNR

EON Resources Signs Expanded Non-Binding LOI With Enstream Capital Management For $52.8M In A Revenue Sharing And Volumetric Funding Arrangement

UnitedHealth's Optum Rx Plans To Align Payment Models More Closely To The Costs Pharmacies May Face Due To Manufacturer Pricing Actions

Stifel analyst Mark Astrachan maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Hold and lowers the price target from $130 to $120.

Price Target

Analyst Ratings

Stifel Maintains Hold on Target, Lowers Price Target to $120

WIIM

FIVE

Five Below shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.

Based on actions previously taken, exposure to tariffs in China, Mexico, and Canada, which collectively represent less than 5% of own sourced product, are expected to impact gross margin by less than 10 basis points.

Guidance

DXLG

Destination XL Says Not Providing FY25 Sales And Earnings Guidance, Citing Volatility Of The Market And Other Macro Uncertainties Such As Tariffs

Corporate updates
<ul>
<li>Executed on 29% reduction in headcount in Q1 2025 as part of approximately $300 million in aggregate cost savings over the next four years to enable goal of achieving operating profitability during 2027</li>
<li>Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years</li>
<li>Engaged TD Cowen to evaluate strategic options for the Company and for all its programs</li>
</ul>

Health Care

General

ADAP

Adaptimmune Says 2024 Annual Report, Set To Be Filed On Monday, March 24, Will State That There Are Serious Concerns About The Company's Ability To Stay In Business, At The End Of 2024, Adaptimmune Had Total Liquidity Of $152M

IONQ

IonQ And Ansys Highlight Demonstration Showing LS-DYNA Applications Simulated Blood Pump Dynamics

First contract has onboarded over 1,000 accounts with 50,000+ more accounts expected in 2025. Second contract to onboard over 900,000 accounts over a 12-month period beginning Q2 2025. These new contracts reinforce 2025 revenue outlook of $80 million to $90 million.
 &nbsp;
 &nbsp;
 &nbsp;

RVYL

RYVYL Subsidiary RYVYL EU Secures Two PaaS Sontracts; New Contracts Reinforce 2025 Revenue Outlook

Reiterates 2025 Outlook
<ul>
<li>Revenue Guidance: Revenue for the year ended December 31, 2025, is expected to reach between EUR 117.5 million and EUR 123.0 million, representing double digit growth compared to 2024.</li>
<li>Adjusted EBITDA Guidance: Adjusted EBITDA is forecasted to range between EUR 19.0 million and EUR 21.5 million, compared to EUR 15.8 million in 2024, supported by a shift toward higher-margin product offerings.</li>
<li>2025e guidance (midpoint) Projects revenue increasing by 17.9% to EUR 120.25 million, EBITDA rising by 28.2% to EUR 20.25 million, and the EBITDA margin improving by 140 basis points to 16.8%.</li>
</ul>

BRAG

Bragg Gaming Group Sees 2025 Revenue Of EUR117.5M-EUR123.0M

LASE

Laser Photonics Receives Two-System Order From Glaze Tool And Engineering, Terms Not Disclosed

Earnings

BBGI

Beasley Broadcast Group Q4 EPS $(1.17); Sales $67.285M Up From $65.748M YoY

With the four-year-long contentious legal battle between Ripple Labs and the Securities and Exchange Commission (SEC) finally over, optimism in the growth potential of XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) could increase by leaps and bounds.
What happened: The legal resolution, confirmed by Ripple CEO Brad Garlinghouse on Wednesday, drove XRP over 7% higher, while its Open Interest surged 17% over the previous day, reflecting heightened speculation for the $10 billion-worth coin.
The dispute, which began in December 2020 with the SEC asserting that XRP was an unregistered security, finished with a decision that partially favored Ripple, affirming that the sale of <a href="https://in.benzinga.com/25/03/44294333/xrp-gains-on-report-that-ripple-sec-case-could-end-soon">XRP to individual investors</a> didn't violate any laws.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44390616/cathie-wood-believes-most-memecoins-wont-face-fearsome-declines-end-up-becoming-collectors-items">Cathie Wood Believes Most Memecoins Will Face &#8216;Fearsome Declines,&#8217; But They Could End Up Becoming Collector&#8217;s Items</a>
During these four years, the coin endured the ups and downs of the market, with the uncertainty testing the resolve of optimists.
The agency sued Ripple on Dec. 22, 2020, sending XRP down 13% to $0.448. Assume you invested $1,000 even after this significant bearish trigger. You would have received 2232.14 units of XRP.&nbsp;
Cut to today when the charges have been dropped. XRP was trading at $2.45 per unit, meaning the original investment would have turned $5468.75, netting a massive 446% return in just under four and a half years.
Investing in an asset during its worst times is a test of long-term conviction. While resilient investors have benefited, those eyeing entry now could monitor fundamental developments and technical levels&nbsp;to make their choice.
The <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">bull case</a> for XRP in 2025 is $5.81, while the bearish prediction was $2.05.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44363871/peter-schiff-slams-bitcoin-etfs-calls-selling-gold-for-btc-worst-timed-trade-in-history">Peter Schiff Slams Bitcoin ETFs, Calls Selling Gold For BTC &#8216;Worst-Timed Trade In History&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$XRP

If You Invested $1000 In XRP Shortly After SEC Sued Ripple Labs, Here's How Much It'd Be Worth Today

QBTS

D-Wave Publishes New Research Paper Introducing Novel Blockchain Architecture That Uses Techniques From Its Quantum Supremacy Demonstration

GAMB

Gambling.com Reaffirms FY25 Revenue Outlook Of $170M - $174M Vs. $167.76M Est.

Earnings Misses

CGTX

Cognition Therapeutics FY 2024 EPS $(0.86) Misses $(0.76) Estimate

CORRECTION: Darden Restaurants Sees FY25 Sales ~$12.1B vs $12.092B Est., Sees FY25 Adj. EPS $9.45-$9.52 vs $9.48 Est.

The company will continue to provide updates on key initiatives throughout the remainder of the year.

PLUG

Plug Power Says CEO Andy Marsh Has Committed To Accept 50% Of His Annual Salary In The Form Of Company Stock This Year

Biotech

SPRY

ARS Pharmaceuticals Says $314M In Cash, Cash Equivalents, And Short-term Investments At Year-end 2024, Supporting An Increased Investment In Commercialization In 2025 While Maintaining An Operating Runway Of At Least Three Years

Press Releases

BranchOut Food Announces Closing of $1.4 Million Follow-On Public Offering

BranchOut Food Inc. Announces $3.925M CEO-led Investment Including an Insider PIPE and Convertible note

Restaurants

BranchOut Food Delivers Shareholder Update: 2024 Revenue Surges 640% in First Half, Poised for Continued Growth and Debt Elimination by Q4 2025

A New Standard in Drug Testing: Intelligent Bio (NASDAQ: INBS) Delivering Cost-Efficiency, Rapid Results, and Employee Dignity more stocks inside…

BranchOut Food Shareholder Update: Projects $15M Run Rate and Positive Cash Flow for Q1 2025 Amid Surge in New Orders as Peru Factory Opens

BranchOut Food Inc. Signs LOI and receives $250K PO from Leading Ingredient Distributor, Definitive Agreement Targeting $5-6M in 2025 Ingredient Sales

BranchOut Food Projects $9 Million in H1 2025 Revenue, Highlighted by $4 Million from Nation's Largest Warehouse Club

Management

BranchOut Food Welcomes Jesse Thomas as Chief Brand Officer to Drive Direct-to-Consumer and Brand Strategy

BranchOut Food Secures $600K+ Order from the Midwest Region of the Nation's Largest Warehouse Club, Driving Bell Pepper Crisps Expansion Across Four Regions

BranchOut Food Signs Definitive Agreement with MicroDried to Revolutionize the $36 Billion Dried Ingredient Market, Projecting $5-6 Million Annual Revenue Surge

Comments

Branchout Food

Intérêt court

Branchout Food (NASDAQ:BOF) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL